Skip to content

Clinical trials

Cardiomyopathies trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathies Clear all

550 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20016
20025
20036
200410
200511
200617
200715
200817
200913
201022
201113
201217
201318
201433
201524
201627
201713
201826
201918
202034
202130
202235
202330
202435
202525
202633

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed255
Recruiting103
Unknown status94
Terminated29
Active, not recruiting21
Not yet recruiting19
Withdrawn13
Enrolling by invitation9
Suspended5
No longer available1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)14
Mayo Clinic11
Assistance Publique - Hôpitaux de Paris10
Alnylam Pharmaceuticals9
Abbott Medical Devices8
Emory University8
Lexeo Therapeutics6
University Hospital, Bonn6
Assiut University5
Eidos Therapeutics, a BridgeBio company5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathies550
Heart Failure179
Heart Diseases58
Cardiovascular Diseases52
Arrhythmias, Cardiac38
Cardiomyopathy, Dilated35
Amyloidosis33
Cardiomyopathy, Hypertrophic29
Death, Sudden, Cardiac27
Myocarditis27

Trials

Showing 76 to 100 of 550. Each trial links to its page on Pharma Observatory.

450 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.